Proteinase K CAS 39450-01-6

Molecular Formula: C29H27N2O12P

Formula Weight: 626.504641

ZSpharmac: Proteinase K Supplement

Product Name: Proteinase K

CAS No: 39450-01-6

Purity: 99%

Basic Info

Product Name:	Proteinase K
Other Names:	Proteinase
CAS:	39450-01-6
Place of Origin:	Shandong, China
Brand Name:	ZSpharmac
Type:	Pharmaceutical Raw Materials
Appearance:	White Powder
EINECS No.:	254-457-8
Storage:	2-8°C
Provide:	Proteinase K MSDS； Proteinase K COA

What is Proteinase K?

Proteinase K, a potent proteolytic enzyme isolated from Candida albicans, is a serine protease related to subtilisin. It is named proteinase K because of its ability to degrade keratin. With high specific activity, it is a key reagent for DNA extraction. This enzyme has activity in wider pH range (4～12.5) and high temperature (50～70 ℃), is used for the separation of plasmid or genomic DNA, RNA.

Proteinase K Properties:

storage temp.	2-8°C
solubility	H₂O: 10 mg/mL, slightly hazy, brown-yellow
form	powder
color	white
PH	pH7.5～12
Water Solubility	Miscible with water.

Proteinase K Uses

Proteinase K is called proteinase K as a result of its capability to absorb keratin (kratin). The proteinase K family consists of a range of intracellular peptidases secreted by fungis, yeast and also Gram-negative germs, amongst which the enzymes produced by germs share a high degree of sequence similarity (> 55%). Yeast albicans (Tritirachium albumLimber) produced proteinase K is the design healthy protein of this family members. Proteinase K has bosom activity on the majority of substratums, yet favors peptide chains with aliphatic and fragrant hydrocarbons. It is a serine protease with a regular serine energetic site: Asp39– His69– Ser224. It contains a single peptide chain with 277 amino acids, 2 disulfide bonds, a vacant cysteine website as well as 2 calcium ion binding sites. The application of proteinase K is generally to get rid of DNase as well as RNase during nucleic acid removal, to get rid of histone bound to the genome, and also to suspend alkaline phosphatase. Presently, molecular biology innovation has actually been applied to numerous detection standards, such as genetically customized detection, pet characteristic discovery, pathogenic microbe discovery, and so on. In molecular biology discovery, the extraction quality of nucleic acid directly impacts the amplification efficiency of subsequent PCR responses. Several criteria include the addition of proteinase K food digestion to the nucleic acid extraction action in order to extract purer nucleic acids. In order to shield nucleic acids, molecular biology nucleic acid extraction experiments generally have reagents such as EDTA. Because EDTA can complicated with steel ions, the enzymatic task may be influenced; as well as digestion is generally accomplished at pH 8.0 as well as 55 ° C. Enzyme task is impacted by different pH and also temperature problems.
Proteinase K is used to suspend nucleotidase healthy proteins during DNA as well as RNA isolation. Get rid of endotoxin binding to cationic healthy proteins such as lysozyme as well as ribonuclease. Research records reveal that enzymes on cell membranes are made use of to isolate liver, yeast, and also mung bean mitochondria for antibody labeling, and antigen-binding sites are subjected in paraffin-embedded cells areas. Digestion of proteins from mind tissue examples for the study of prion transmissible spongiform encephalopathy (TSE).

Properties of Proteinase K

Molecular Structure
Proteinase K consists of a peptide chain containing 277 amino acid residues with a relative molecular mass of 28 930. The active site is composed of D39, H69 and S224, and the substrate recognition sites are mainly two fragments, G100-Y104 and S132-G136. The amino acid sequence of proteinase K has a high degree of homology to subtilisins and is therefore classified as subtilisins. Proteinase K belongs to the α/β class of proteins comprising 6 α-helices, 15 β-sheets and one 3/10 helix. Fluorescence
Proteinase K is excited at 295 nm, and its fluorescence is determined by two tryptophan residues, W8 and W212. However, the photoreactivity of the two tryptophans was different, and W212 was much more reactive. The tryptophan fluorescence quantum yield was constant in the pH range of 3-9. For thermal inactivation of excited tryptophan, an activation energy of 54 kJ/mol is required. This value is substantially higher than other proteases from microorganisms, and thus can be used to explain the higher thermostability of proteinase K. Enzymatic properties
Proteinase K has high cleavage activity, and the substrate recognition site can form a three-stranded anti-parallel β-sheet with the substrate, which can catalyze the cleavage of the carboxy-terminal peptide bonds of aliphatic and aromatic amino acids. The α-helix is the main structure that maintains the conformational stability of the proteinase K active center. The α-helix contains a total of 90 amino acid residues, accounting for 1/3 of the total number of residues, most of which are in the extended β-sheet structure. This results in a low degree of order of the entire molecule, low denaturation entropy, and extremely low specific denaturation enthalpy, reflecting the nature of enzyme stability. Two disulfide bonds and two Ca2+ in the molecule also contribute to the thermal stability of the tertiary structure. pH, temperature, Ca2+, activators and inhibitors are the main factors affecting the activity of proteinase K.

Proteinase K Clinical Studies

Phase I clinical study

Relacatib: Its effect on the metabolism of ibuprofen, paracetamol and atorvastatin was determined in a phase I trial. Although early data showed great potential, late clinical studies were not carried out due to potential drug-drug interactions. Balicatib: Results from a phase I study showed a dose-dependent increase in lumbar spine (+4.4%) and hip (+2.2%) bone BMD, as well as a dose-dependent decrease in bone resorption-related markers (serum CTX 61% and urine NTX 55%). The study of the drug was eventually discontinued due to safety concerns after patients with balicatib were found to have symptoms of scleroderma. A three-phase I trial of odanacatib was conducted to examine safety, tolerability, pharmacokinetics and pharmacodynamics. Three results showed that no serious adverse effects occurred in the short-term study and that odanacatib was well tolerated. A recent report studied safety, tolerability, pharmacokinetics and pharmacodynamics in 44 healthy volunteers (36 men and 8 postmenopausal women) and again showed relatively good tolerability.

Phase II clinical study

ONO-5334: As seen in the Phase I clinical study of balicatib, both ONO-5334 and alendronate reduced biochemical markers of bone resorption by 50-70%, with only ONO-5334 at the highest at 300 mg/day At doses, there was a modest reduction in markers of bone formation. Additional studies found that ONO-5334 treatment at 300 mg/day resulted in a sustained increase in bone mineral density (lumbar spine +6.7%, hip +3.4%, femur +3.7%) and reduced serum CTX and urine NTX levels, but Markers of bone formation were not significantly reduced. Notably, discontinuation of treatment after 24 months of treatment resulted in higher urinary NTX and serum TRAP5b levels than baseline, suggesting reversibility of proteinase K inhibitors. However, a review of clinical trials did not reveal any clinical trials involving ONO-5334.

Phase III clinical study

Odanacatib is still the most studied at present, and the research results show that it has great potential research value, Fig5. Of final concern is the difference between odanacatib and placebo-treated patients, with odanacatib having an increased risk of cardiovascular and cerebrovascular disease (though not reaching statistical significance), according to the 2016 Bone and Mineral Annual Meeting in America, adjudicated Atrial fibrillation and atrial flutter events were more common in Odanacatib-treated patients, but the difference did not reach statistical significance. Based on these analyses, the study sponsor eventually withdrew from the Odanacatib study. Although there are many difficulties in the study of proteinase K inhibitors, it also provides a new idea for the study of osteoporosis treatment. Proteinase K inhibitors are a new direction for the treatment of osteoporosis. While currently available antiresorptive agents reduce osteoclast activity and number, resulting in reduced bone resorption, they can lead to reduced bone formation. Proteinase K inhibitors have less effect on bone formation while reducing bone resorption. However, unlike the primary biological target of phosphates, which are osteoclasts, proteinase K inhibitors have the potential to affect other tissues, and this potential risk has limited the development of all proteinase K inhibitors except Odanacatib.

About Us

The production base is located in Zhangqiu chemical industry park and Tai’an high-tech chemical industry park. laboratory and workshop in strict accordance with the GMP standard and the product fit national ISO9001 and ISO2000 standards.

“Zhishang” products are exported to Europe, North and South America, the Middle East, Asia Pacific and Africa area, so as to establish a long-term and stable cooperation relationship with customer in the world.

Company Info

Business Type: Manufacturer
Product Range: Additive , Chemical Auxiliary & Catalyst , Organic Chemicals
Products/Service: Organic Intermediate,Inorganic Chemistry, APIs, Dyestuffs And Pigments, Fragrance And Spices, Food Additives
Total Employees: 51~100
Capital (Million US $): 10000000RMB
Year Established: 2016

Production Capacity

No. of Production Lines : 8
No. of QC Staff : 5 -10 People
OEM Services Provided : yes
Factory Size (Sq.meters) : 3,000-5,000 square meters
Certificate: ISO9001 , CE , GMP , API , MSDS
Factory Location : Diao Town Industry Park, Zhangqiu City, Jinan City, Shandong Province, China.

Service

Pre-Sales Service

* Prompt reply and 24 hours online, professional team to provide best price and high quality product.

* Sample testing support.

* Every batch of products will be tested to ensureits quality.

*The packing also can be according the customers` requirment.

*Any inquiries will be replied within 24 hours.

*we provide Commerical Invoice, Packing List, Bill of loading, COA , Health certificate and Origin certificate. If your markets have any special requirements, let us know.

After-Sales Service

*The fact of logistics information monitoring.

* Any questions about the product can be consulted at any time.

*Product has any problem can return.

FAQ

Do you accept sample order?

We will make samples before mass production, and after sample approved, we’ll begin mass production. Doing 100% inspection during production, then do random inspection before packing.

HOW TO CONFIRM THE PRODUCT QUALITY BEFORE PLACING ORDERS?

You can get free samples for some products,you only need to pay the shipping cost or arrange a courier to us and take the samples. You can send us your product specifications and requests,we will manufacture the products according to your requests.

What’s your MOQ?

Our MOQ is 1kg. But usually we accept less quantity such as 100g on the condition that sample charge is 100% paid.

Do you supply product report?

Yes. We’ll give you product analysis report before shipping.

Is there a discount?

Different quantity has different discount.

Shipping

1. ≤50kg, Express delivery recommended, usually called as DDU service;

2. ≤500kg, Air shipping recommended, usually called as FOB, CFR, or CIF service;

3. >500kg, sea shipping recommended, usually called as FOB, CFR, or CIF service;

4. For high value products, please select air shipping and express delivery for safe.